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P2Y1 receptor antagonists are being developed as anti-
thrombotics. In the vasculature, P2Y1 receptors are not
only expressed in platelets, but also in the endothelium
where they indirectly mediate vasorelaxation. By blockade
of these latter effects, P2Y1 antagonists may cause unto-
ward effects. Here, we investigated whether vascular sym-
pathetic axon terminals also possess P2Y1 receptors by
determining [3H]noradrenaline release from superior cer-
vical ganglion neurons in cell culture. ADP inhibited elec-
trically evoked release, but this effect was reverted into
facilitation when either P2Y12 receptors were blocked by
cangrelor or their signalling cascade was interrupted by
pertussis toxin. The facilitation by ADP was also observed
with K+ stimulation in the presence of tetrodotoxin, was
mimicked by 2-methlythio-ATP, and was prevented by
suramin, reactive blue 2, and MRS2179. The facilitation
by ADP was abolished by the phospholipase C inhibitor
U73122, but was not affected by cholera toxin to down-
regulate Gs proteins, by H-7 to block protein kinases, or by
thapsigargin to deplete intracellular Ca2+ stores. In patch
clamp recordings, activation of P2Y1 receptors led to an
inhibition of KCNQ channels, but the KCNQ channel
modulators retigabine and XE 991 did not alter electri-
cally evoked noradrenaline release or its facilitation by
ADP. These results show that presynaptic P2Y1 receptors
mediate facilitation of transmitter release from sympa-
thetic nerve terminals via phospholipase C, and interfer-
ence with this mechanism by P2Y1 antagonists can be
expected to counteract the previously described vasocon-
strictive action of these drugs.
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